Delivery Order SPE2DB22D1002-SPE2DB26FKSV3
- Not listed
- The Defense Logistics Agency awarded a $1,638.00 delivery order to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with a completion date of September 10, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $1,683.86 to AmerisourceBergen Drug Corp for Copaxone 20 mg/ml syringes, with a completion date of August 27, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The pharmaceutical product will be delivered to AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and operates as a major...
- The Defense Logistics Agency awarded a delivery order valued at $2,580.20 to AmerisourceBergen Drug Corp for the supply of Copaxone 40 mg/ml syringes. The contract, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, utilizes firm fixed price terms and was competitively awarded without set-aside provisions. AmerisourceBergen's Corporate Office, located in Conshohocken, Pennsylvania, serves as the place of performance for this delivery order. This delivery order is...
- The Defense Logistics Agency awarded a $1,092.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with a completion date of September 11, 2025. This non-set-aside competitive award represents a single delivery order issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $6,202.79 to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with an ultimate completion date of September 18, 2025. This is a firm fixed price, non-set-aside contract performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader federal procurement relationship supporting military and federal healthcare systems....
- The Defense Logistics Agency awarded a $2,718.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with completion scheduled for September 15, 2025. This non-set-aside contract represents a competitively awarded delivery order issued under AmerisourceBergen's broader pharmaceutical supply vehicle with DLA. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order valued at $10,510.43 to AmerisourceBergen Drug Corp for the supply of Copaxone 20 mg/ml syringes. The contract, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, carries firm fixed pricing with no set-aside designation, indicating competitive award status. Performance will occur at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract executed...
- The Defense Logistics Agency awarded a $2,730.00 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Copaxone 40 mg/mL syringes. This firm fixed price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product will be delivered to the company's corporate headquarters location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,989.35 to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with completion scheduled for July 22, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement typical of pharmaceutical procurement through the federal medical supply chain. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $1,954.30 to AmerisourceBergen Drug Corp for Copaxone 40 mg/ml syringes, with an ultimate completion date of June 5, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed through the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB26FKSV3Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,218.86 to supply Copaxone 40 mg/mL syringes. This competitively awarded, firm fixed-price contract, issued on October 15, 2025, with an ultimate completion date of October 16, 2025, represents a direct fulfillment of pharmaceutical needs through the company's existing indefinite delivery vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and prime vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare systems and other federal agencies. Copaxone, an immunosuppressant used to treat multiple sclerosis, aligns with the company's portfolio of specialty medications and neurological treatments delivered through its global pharmaceutical support vehicle serving the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 10/15/25 |